# Study to Assess the Safety, Tolerability, PK and PD of ABX1100

> **NCT06109948** · EARLY_PHASE1 · COMPLETED · sponsor: **Aro Biotherapeutics** · enrollment: 46 (actual)

## Conditions studied

- Healthy
- Late Onset Pompe Disease

## Interventions

- **DRUG:** ABX1100 injection for IV infusion
- **DRUG:** Placebo injection for IV infusion

## Key facts

- **NCT ID:** NCT06109948
- **Lead sponsor:** Aro Biotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-10-19
- **Primary completion:** 2026-02-13
- **Final completion:** 2026-02-13
- **Target enrollment:** 46 (ACTUAL)
- **Last updated:** 2026-05-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06109948

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06109948, "Study to Assess the Safety, Tolerability, PK and PD of ABX1100". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06109948. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*